Type I collagen and its daughter peptides for targeting mucosal healing in ulcerative colitis: A new treatment strategy

European Journal of Pharmaceutical Sciences

Volumn 91, Issue , 2016, Pages 216-224

  Ramadass, Satiesh Kumar ^a   Jabaris, Sugin Lal ^b   Perumal, Ramesh Kannan ^a   HairulIslam, Villianur Ibrahim ^c   Gopinath, Arun ^a   Madhan, Balaraman ^a  

^a CENTRAL LEATHER RESEARCH INSTITUTE   (India)

^b Siddha Central Research Institute   (India)

^c Pondicherry Centre for Biological Sciences   (India)

Author keywords

Collagen; Collagen hydrolysate; Mucosal damage; Ulcerative colitis

Indexed keywords

COLLAGEN TYPE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESALAZINE; PROTEIN HYDROLYSATE; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; DEXTRAN SULFATE; FIBROBLAST GROWTH FACTOR; MESSENGER RNA; PEPTIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL ASSESSMENT; CLINICAL INDICATOR; CONTROLLED STUDY; DEXTRAN SODIUM SULFATE-INDUCED COLITIS; DOWN REGULATION; DRUG TARGETING; HEALING; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECTUM HEMORRHAGE; TISSUE ENGINEERING; ULCERATIVE COLITIS; ANIMAL; BAGG ALBINO MOUSE; CHEMICALLY INDUCED; COLON; DRUG DELIVERY SYSTEM; DRUG EFFECT; GENETICS; INTESTINE MUCOSA; MALE; METABOLISM; PATHOLOGY;

ANIMALS; COLITIS, ULCERATIVE; COLLAGEN TYPE I; COLON; CYTOKINES; DEXTRAN SULFATE; DRUG DELIVERY SYSTEMS; FIBROBLAST GROWTH FACTORS; INTESTINAL MUCOSA; MALE; MICE, INBRED BALB C; PEPTIDES; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84969963404     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2016.05.015     Document Type: Article

References (45)

1. Bafutto, M., Almeida, J.R.D., Leite, N.V., Oliveira, E.C., Gabriel-Neto, S., Rezende-Filho, J., Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine. Arq. Gastroenterol. 48 (2011), 36–40.
2. Baugh, M.D., Perry, M.J., Hollander, A.P., Davies, D.R., Cross, S.S., Lobo, A.J., Taylor, C.J., Evans, G.S., Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology 117 (1999), 814–822.
3. Bornstein, P., Sage, H., Structurally distinct collagen types. Annu. Rev. Biochem. 49 (1980), 957–1003.
4. Boyer, D., Cultural considerations in advanced wound care. Adv. Skin Wound Care 26 (2013), 110–111.
5. Brynskov, J., Tvede, N., Andersen, C.B., Vilien, M., Increased concentrations of interleukin 1 beta, interleukin-2, and soluble interleukin-2 receptors in endoscopical mucosal biopsy specimens with active inflammatory bowel disease. Gut 33 (1992), 55–58.
6. D'Haens, G., Sandborn, W.J., Feagan, B.G., Geboes, K., Hanauer, S.B., Irvine, E.J., Lemann, M., Marteau, P., Rutgeerts, P., Scholmerich, J., Sutherland, L.R., A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 132 (2007), 763–786.
7. DiCosmo, F., Edge effect: the role of collagen in wound healing. Adv. Skin Wound Care 22 (2009), 12–15.
8. Elson, C.O., The basis of current and future therapy for inflammatory bowel disease. Am. J. Med. 100 (1996), 656–662.
9. Elson, C.O., Sartor, R.B., Tennyson, G.S., Riddell, R.H., Experimental-models of inflammatory bowel-disease. Gastroenterology 109 (1995), 1344–1367.
10. Ficai, A., Albu, M.G., Birsan, M., Sonmez, M., Ficai, D., Trandafir, V., Andronescu, E., Collagen hydrolysate based collagen/hydroxyapatite composite materials. J. Mol. Struct. 1037 (2013), 154–159.
11. Froslie, K.F., Jahnsen, J., Moum, B.A., Vatn, M.H., Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 133 (2007), 412–422.
12. Griga, T., Tromm, A., Spranger, J., May, B., Increased serum levels of vascular endothelial growth factor in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 33 (1998), 504–508.
13. Griga, T., Voigt, E., Gretzer, B., Brasch, F., May, B., Increased production of vascular endothelial growth factor by intestinal mucosa of patients with inflammatory bowel disease. Hepato-Gastroenterology 46 (1999), 920–923.
14. Hartmann, G., Bidlingmaier, C., Siegmund, B., Albrich, S., Schulze, J., Tschoep, K., Eigler, A., Lehr, H.A., Endres, S., Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice. J. Pharmacol. Exp. Ther. 292 (2000), 22–30.
15. Kamm, M.A., Lichtenstein, G.R., Sandborn, W.J., Schreiber, S., Lees, K., Barrett, K., Joseph, R., Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. Inflamm. Bowel Dis. 15 (2009), 1–8.
16. Kanazawa, S., Tsunoda, T., Onuma, E., Majima, T., Kagiyama, M., Kikuchi, K., VEGF, basic-FGF, and TGF-beta in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation. Am. J. Gastroenterol. 96 (2001), 822–828.
17. Kusugami, K., Fukatsu, A., Tanimoto, M., Shinoda, M., Haruta, J., Kuroiwa, A., Ina, K., Kanayama, K., Ando, T., Matsuura, T., et al. Elevation of interleukin-6 in inflammatory bowel disease is macrophage- and epithelial cell-dependent. Dig. Dis. Sci. 40 (1995), 949–959.
18. Leblond, C.P., Inoue, S., Structure, composition, and assembly of basement membrane. Am. J. Anat. 185 (1989), 367–390.
19. Lichtenstein, G.R., Rutgeerts, P., Importance of mucosal healing in ulcerative colitis. Inflamm. Bowel Dis. 16 (2010), 338–346.
20. Lichtenstein, G.R., Kamm, M.A., Boddu, P., Gubergrits, N., Lyne, A., Butler, T., Lees, K., Joseph, R.E., Sandborn, W.J., Effect of once-or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin. Gastroenterol. Hepatol. 5 (2007), 95–102.
21. Ligumsky, M., Simon, P.L., Karmeli, F., Rachmilewitz, D., Role of interleukin 1 in inflammatory bowel disease–enhanced production during active disease. Gut 31 (1990), 686–689.
22. Livak, K.J., Schmittgen, T.D., Analysis of relative gene expression data using real-time quantitative PCR and the 2(T)(− Delta Delta C) method. Methods 25 (2001), 402–408.
23. Louis, E., The immuno-inflammatory reaction in Crohn's disease and ulcerative colitis: characterisation, genetics and clinical application. Focus on TNF alpha. Acta Gastroenterol. Belg. 64 (2001), 1–5.
24. Low, D., Nguyen, D.D., Mizoguchi, E., Animal models of ulcerative colitis and their application in drug research. Drug Des. Devel. Ther. 7:1 (2013), 1341–1357.
25. MacDonald, T.T., Hutchings, P., Choy, M.Y., Murch, S., Cooke, A., Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin. Exp. Immunol. 81 (1990), 301–305.
26. Melgar, S., Karlsson, A., Michaelsson, E., Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. Am. J. Phys. 288 (2005), G1328–G1338.
27. Mikalsen, L.T., Dhakal, H.P., Bruland, O.S., Nesland, J.M., Olsen, D.R., Quantification of angiogenesis in breast cancer by automated vessel identification in CD34 immunohistochemical sections. Anticancer Res. 31 (2011), 4053–4060.
28. Odze, R., Diagnostic problems and advances in inflammatory bowel disease. Mod. Pathol. 16 (2003), 347–358.
29. Okayasu, I., Hatakeyama, S., Yamada, M., Ohkusa, T., Inagaki, Y., Nakaya, R., A novel method in the induction of reliable experimental acute and chronic ulcerative-colitis in mice. Gastroenterology 98 (1990), 694–702.
30. Paunovic, B., Deng, X., Khomenko, T., Ahluwalia, A., Tolstanova, G., Tarnawski, A., Szabo, S., Sandor, Z., Molecular mechanisms of basic fibroblast growth factor effect on healing of ulcerative colitis in rats. J. Pharmacol. Exp. Ther. 339 (2011), 430–437.
31. Pei, Y., Yang, J., Liu, P., Xu, M., Zhang, X., Zhang, L., Fabrication, properties and bioapplications of cellulose/collagen hydrolysate composite films. Carbohydr. Polym. 92 (2013), 1752–1760.
32. Ramadass, S.K., Perumal, S., Jabaris, S.L., Madhan, B., Preparation and evaluation of mesalamine collagen in situ rectal gel: a novel therapeutic approach for treating ulcerative colitis. Eur. J. Pharm. Sci. 48 (2013), 104–110.
33. Ramadass, S.K., Perumal, S., Gopinath, A., Nisal, A., Subramanian, S., Madhan, B., Sol-gel assisted fabrication of collagen hydrolysate composite scaffold: a novel therapeutic alternative to the traditional collagen scaffold. ACS Appl. Mater. Interfaces 6 (2014), 15015–15025.
34. Rossetti, S., Actis, G.C., Fadda, M., Rizzetto, M., Palmo, A., The use of the anti-tumour necrosis factor monoclonal antibody–infliximab–to treat ulcerative colitis: implications and trends beyond the available data. Dig. Liver Dis. 36 (2004), 426–431.
35. Ruszczak, Z., Effect of collagen matrices on dermal wound healing. Adv. Drug Deliv. Rev. 55 (2003), 1595–1611.
36. Rutgeerts, P., Vermeire, S., Van Assche, G., Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?. Gut 56 (2007), 453–455.
37. Sandor, Z., Deng, X.M., Khomenko, T., Tarnawski, A.S., Szabo, S., Altered angiogenic balance in ulcerative colitis: a key to impaired healing?. Biochem. Biophys. Res. Commun. 350 (2006), 147–150.
38. Sands, B.E., Biologic therapy for inflammatory bowel disease. Inflamm. Bowel Dis. 3 (1997), 95–113.
39. Sands, B.E., Therapy of inflammatory bowel disease. Gastroenterology 118 (2000), S68–S82.
40. Sartor, R.B., Cytokines in intestinal inflammation - pathophysiological and clinical considerations. Gastroenterology 106 (1994), 533–539.
41. Siegmund, B., Fantuzzi, G., Rieder, F., Gamboni-Robertson, F., Lehr, H.A., Hartmann, G., Dinarello, C.A., Endres, S., Eigler, A., Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. Am. J. Physiol.-Reg. I 281 (2001), R1264–R1273.
42. Tanaka, S., Avigad, G., Eikenberry, E.F., Brodsky, B., Isolation and partial characterization of collagen chains dimerized by sugar-derived cross-links. J. Biol. Chem. 263 (1988), 17650–17657.
43. Tolstanova, G., Khomenko, T., Deng, X., Chen, L., Tarnawski, A., Ahluwalia, A., Szabo, S., Sandor, Z., Neutralizing anti-vascular endothelial growth factor (VEGF) antibody reduces severity of experimental ulcerative colitis in rats: direct evidence for the pathogenic role of VEGF. J. Pharmacol. Exp. Ther. 328 (2009), 749–757.
44. Wang, Y.D., Mao, J.W., Expression of matrix metalloproteinase-1 and tumor necrosis factor-alpha in ulcerative colitis. World J. Gastroenterol. 13 (2007), 5926–5932.
45. Wang, Y.D., Yan, P.Y., Expression of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in ulcerative colitis. World J. Gastroenterol. 12 (2006), 6050–6053.